Literature DB >> 32683478

Risk factors of cemented vertebral refracture after percutaneous vertebral augmentation: a systematic review and meta-analysis.

Shiqi Zhu1, Qingjun Su1, Yaoshen Zhang1, Zhencheng Sun1, Peng Yin2, Yong Hai1.   

Abstract

To evaluate the risk factors of cemented vertebral refracture after percutaneous vertebral augmentation (PVA) for patients with osteoporotic vertebral compression fractures (OVCFs). We performed a literature search on cemented vertebral refracture after PVA using the PubMed, EMBASE, and Cochrane Library medical databases. The clinical data, including literature information, basic patient information, observational factors, and interventional factors, were extracted by two authors. The pooled results and related heterogeneity of each factor between the refracture group and the non-refracture group were evaluated using Review Manager software 5.35. A total of 3185 patients from 10 studies were included, with 195 patients in the refracture group and 2990 patients in the non-refracture group. The mean follow-up duration was 18.9 months. According to the meta-analysis, age, low bone marrow density (BMD), intravertebral cleft (IVC), high anterior vertebral height (AVH) restoration/high Cobb angle restoration, and low cement dose were the risk factors of cemented vertebral refracture after PVA. Our results showed that age, low BMD, IVC, high AVH restoration, high Cobb angle restoration, and low cement dose were the risk factors for cemented vertebral refracture after PVA.

Entities:  

Keywords:  Meta-analysis; Osteoporotic vertebral compression fracture; Percutaneous vertebral augmentation; Refracture; Risk factor

Mesh:

Substances:

Year:  2020        PMID: 32683478     DOI: 10.1007/s00234-020-02495-9

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  1 in total

1.  Intervertebral bridging ossification after kyphoplasty in a Parkinson's patient with Kummell's disease: A case report.

Authors:  Jie Li; Yun Liu; Lei Peng; Jian Liu; Zhi-Dong Cao; Miao He
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.